Biotin-VAD-FMK

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Biotin-VAD-FMK  纯度: ≥98.0%

Biotin-VAD-FMK是可渗透细胞的,不可逆的,由生物素标记的胱天蛋白酶抑制剂,用于鉴定细胞裂解物中的半胱天冬酶活性。

Biotin-VAD-FMK

Biotin-VAD-FMK Chemical Structure

CAS No. : 1135688-15-1

规格 价格 是否有货 数量
1 mg ¥7000 In-stock
5 mg ¥25000 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Biotin-VAD-FMK 相关产品

相关化合物库:

  • Bioactive Compound Library Plus
  • Peptidomimetic Library

生物活性

Biotin-VAD-FMK is a cell permeable, irreversible biotin-labeled caspase inhibitor, used to identify active caspases in cell lysates.

IC50 & Target

Caspase

 

体外研究
(In Vitro)

Biotin-VAD-FMK is a synthetic peptide designed as a methyl ester to facilitate cell permeability.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

To examine whether caspase-2 is activated in the absence of proteolytic cleavage, an in vivo affinity labeling approach is used, using the biotinylated caspase inhibitor biotin-VAD-fmk that detects only active caspases[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

672.81

Formula

C30H49FN6O8S

CAS 号

1135688-15-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 27.3 mg/mL (40.58 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.4863 mL 7.4315 mL 14.8630 mL
5 mM 0.2973 mL 1.4863 mL 2.9726 mL
10 mM 0.1486 mL 0.7432 mL 1.4863 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

参考文献
  • [1]. Li J, et al. Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. J Biol Chem. 1999 Jun 11;274(24):17325-33.

    [2]. Samraj AK, et al. Loss of caspase-9 reveals its essential role for caspase-2 activation and mitochondrial membranedepolarization. Mol Biol Cell. 2007 Jan;18(1):84-93.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Z-VAD-FMK(Synonyms: Z-VAD(OH)-FMK)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Z-VAD-FMK (Synonyms: Z-VAD(OH)-FMK) 纯度: 99.44%

Z-VAD-FMK (Z-VAD(OH)-FMK) 是一种 pan caspase 抑制剂。Z-VAD-FMK 不抑制泛素 C 末端水解酶 L1 (UCHL1) 活性,即使浓度高达 440 μM。

Z-VAD-FMK(Synonyms: Z-VAD(OH)-FMK)

Z-VAD-FMK Chemical Structure

CAS No. : 161401-82-7

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥3090 In-stock
1 mg ¥875 In-stock
5 mg ¥3085 In-stock
10 mg ¥5270 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Z-VAD-FMK 相关产品

相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Anti-Cancer Compound Library
  • Covalent Screening Library

生物活性

Z-VAD-FMK (Z-VAD(OH)-FMK) is a well-know pan caspase inhibitor, which does not inhibit ubiquitin carboxy-terminal hydrolase L1 (UCHL1) activity even at concentrations as high as 440 μM[1].

IC50 & Target[1]

Caspase

 

体外研究
(In Vitro)

Z-VAD-FMK (40 μM) reverses the apoptotic effect exerted by total saponin of Solanum lyratum Thunb (TSSLT) in Hela cells. HeLa cells are pretreated with Z-VAD-FMK (40 μM) for 30 min and exposed to TSSLT (6 μg/mL) for 48 h[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[2]

Cell Line: HeLa cells
Concentration: 40 μM
Incubation Time: Prtreated for 30 minutes
Result: Prevented TSSLT-induced cell death. More than 80% cell survival was observed.

分子量

453.46

Formula

C21H28FN3O7

CAS 号

161401-82-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture and light

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

溶解性数据
In Vitro: 

DMSO : 100 mg/mL (220.53 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.2053 mL 11.0263 mL 22.0527 mL
5 mM 0.4411 mL 2.2053 mL 4.4105 mL
10 mM 0.2205 mL 1.1026 mL 2.2053 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (4.59 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.59 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.08 mg/mL (4.59 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (4.59 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (4.59 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (4.59 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Davies CW, et al. The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK). Bioorg Med Chem Lett. 2012 Jun 15;22(12):3900-4.

    [2]. Liu HR, et al. Antiproliferative activity of the total saponin of Solanum lyratum Thunb in Hela cells by inducing apoptosis. Pharmazie. 2008 Nov;63(11):836-42.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Z-VAD(OMe)-FMK(Synonyms: Z-Val-Ala-Asp(OMe)-FMK)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。

Z-VAD(OMe)-FMK (Synonyms: Z-Val-Ala-Asp(OMe)-FMK) 纯度: ≥98.0%

Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) 是一种不可逆的 pan-caspase 抑制剂。Z-VAD(OMe)-FMK 是泛素 C 末端水解酶 L1 (UCHL1) 抑制剂。Z-VAD(OMe)-FMK 通过靶向 UCHL1 活性位点对 UCHL1 进行不可逆地修饰。

Z-VAD(OMe)-FMK(Synonyms: Z-Val-Ala-Asp(OMe)-FMK)

Z-VAD(OMe)-FMK Chemical Structure

CAS No. : 187389-52-2

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥1748 In-stock
1 mg ¥650 In-stock
5 mg ¥1700 In-stock
10 mg ¥2700 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Z-VAD(OMe)-FMK 相关产品

相关化合物库:

  • Covalent Screening Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Anti-Cancer Compound Library
  • Peptidomimetic Library
  • Covalent Screening Library

生物活性

Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) is a cell-permeable and irreversible pan-caspase inhibitor[1]. Z-VAD(OMe)-FMK is an ubiquitin carboxy-terminal hydrolase L1 (UCHL1) inhibitor. Z-VAD(OMe)-FMK irreversibly modifies UCHL1 by targeting the active site of UCHL1[2].

IC50 & Target[1]

Caspase

 

体外研究
(In Vitro)

Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK) is a broad-spectrum caspase inhibitor, has been shown to inhibit the intracellular activation of caspase-like proteases. The injection of Z-VAD(OMe)-FMK suppresses the caspase-3 activity in lung tissues, and significantly decreases the number of terminal dUTP nick-end labeling-positive cells[1]. Z-VAD(OMe)-FMK effectively inhibits UCHL1’s reaction with hemagglutinin-tagged ubiquitin vinylmethyl ester (HA-UbVME) at the concentration of 100 μM[2]. Z-VAD(OMe)-FMK is administered intraperitoneally at 1 hour before and 6 hours after SAH. Expression of caspase-3 and positive TUNEL is examined as markers for apoptosis. Z-VAD(OMe)-FMK suppresses TUNEL and caspase-3 staining in endothelial cells, decreases caspase-3 activation, reduces BBB permeability, relieves vasospasm, abolishes brain edema, and improves neurological outcome[3]. Z-VAD(OMe)-FMK is a cell-permeable caspase inhibitor, efficiently blocks cell death induced by SMN deficiency[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

The survival rate of mice is prolonged significantly by the injection of Z-VAD(OMe)-FMK (Z-Val-Ala-Asp(OMe)-FMK). All mice succumbed to LPS within 30 hours. By contrast, the mice treated with Z-VAD(OMe)-FMK survive significantly longer and 27% of the mice survived more than 7 days[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

467.49

Formula

C22H30FN3O7

CAS 号

187389-52-2

Sequence

Z-Val-Ala-Asp(OMe)-FMK

Sequence Shortening

ZVA-D(OMe)-FMK

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -80°C 2 years
-20°C 1 year
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (213.91 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.1391 mL 10.6954 mL 21.3908 mL
5 mM 0.4278 mL 2.1391 mL 4.2782 mL
10 mM 0.2139 mL 1.0695 mL 2.1391 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 5% DMSO    40% PEG300    5% Tween-80    50% saline

    Solubility: ≥ 2.62 mg/mL (5.60 mM); Clear solution

  • 2.

    请依序添加每种溶剂: 5% DMSO    95% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.62 mg/mL (5.60 mM); Clear solution

  • 3.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.35 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 4.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.35 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 5.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (5.35 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (5.35 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

  • 6.

    请依序添加每种溶剂: 1% DMSO    99% saline

    Solubility: ≥ 0.52 mg/mL (1.11 mM); Clear solution

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献
  • [1]. Kawasaki M, et al. Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspaseinhibitor. Am J Pathol. 2000 Aug;157(2):597-603.

    [2]. Davies CW, et al. The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK). Bioorg Med Chem Lett. 2012 Jun 15;22(12):3900-4.

    [3]. Park S, et al. Neurovascular protection reduces early brain injury after subarachnoid hemorrhage. Stroke. 2004 Oct;35(10):2412-7.

    [4]. Ilangovan R, et al. Inhibition of apoptosis by Z-VAD-fmk in SMN-depleted S2 cells. J Biol Chem. 2003 Aug 15;278(33):30993-9.

Cell Assay
[4]

PCR products containing coding sequences for the dSMN (forward primer: 5′-TAA TAC GAC TCA CTA TAG GG AAG ACG TAC GAC GAG TCG-3′; and reverse primer: 5′-TAA TAC GAC TCA CTA TAG GG GTG GTG CTG GCT TCT TTC-3′; product length, 601bps; bold and italics letters represent T7 promoter sequences) and control Drosophila Presenilin (dPsn) gene (forward primer: 5′-TAA TAC GAC TCA CTA TAG GG TG GCT GCT GTC AAT CTC-3′; and reverse primer: 5′-TAA TAC GAC TCA CTA TAG GG CGA TAG CAA CGC TTC TTG-3′; product length: 543bps) are obtained and gel-purified. Double-stranded RNAs (dsRNA) are generated by transcription with Ribomax T7 Transcription kit and digested with Rnase-free DNase. The dsRNA products are ethanol precipitated and annealed by incubation at 65°C for 30 min and then slowly allowed to cool at room temperature. The annealed dsRNA products are analyzed on a 1% agaorse gel to ensure the majority of dsRNA existed as a single band. The dsRNA (2 μg) and/or plasmid DNAs (2 μg) are introduced into cells by using Cellfectin. Caspase inhibition is achieved by using 50 μM of Z-VAD(OMe)-FMK in the culture medium[4].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1][3]

Mice[1]
Mice used in this study are 5- to 6-week-old (20 to 22 g) ICR males. Mice are injected with 30 mg/kg LPS from E. coli serotype O111:B4 through the tail vein. A single intravenous injection of Z-VAD(OMe)-FMK (0.25 mg) is made 15 minutes before LPS injection, followed by three intravenous injections of Z-VAD(OMe)-FMK (0.1 mg each) per hour. Control mice are injected with the same volume of 1% DMSO in sterile saline.
Rats[3]
Male Sprague-Dawley rats weighing 300 to 350 g are anesthetized with α-chloralose (40 mg/kg IP) and urethane (400 mg/kg IP). Animals are intubated, and respiration is maintained with a small animal respirator. Rectal temperature is maintained at 37±0.5°C with a heating pad. The left external carotid artery is isolated and a 4.0 monofilament nylon suture is inserted through the internal carotid artery to perforate the middle cerebral artery. SAH is confirmed at autopsy in each rat. Sham-operated rats underwent the same procedures except that the suture is withdrawn after resistance is felt. Z-VAD(OMe)-FMK (50 μM per 0.3 mL) is injected intraperitoneally at 1 hour before and 6 hours after SAH induction. In vehicle group, rats underwent SAH induction and are treated with the same volume of vehicle (DMSO diluted in physiological buffer solution). No treatment is applied in sham-operated animals.

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Kawasaki M, et al. Protection from lethal apoptosis in lipopolysaccharide-induced acute lung injury in mice by a caspaseinhibitor. Am J Pathol. 2000 Aug;157(2):597-603.

    [2]. Davies CW, et al. The co-crystal structure of ubiquitin carboxy-terminal hydrolase L1 (UCHL1) with a tripeptide fluoromethyl ketone (Z-VAE(OMe)-FMK). Bioorg Med Chem Lett. 2012 Jun 15;22(12):3900-4.

    [3]. Park S, et al. Neurovascular protection reduces early brain injury after subarachnoid hemorrhage. Stroke. 2004 Oct;35(10):2412-7.

    [4]. Ilangovan R, et al. Inhibition of apoptosis by Z-VAD-fmk in SMN-depleted S2 cells. J Biol Chem. 2003 Aug 15;278(33):30993-9.

所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

多肽定制Ac-VAD-CHO 编码

上海金畔生物科技有限公司可以定制不同序列多肽,可以访问官网了解更多产品信息。

名称 Ac-VAD-CHO
编码
别名 Ac-VAD-CHO
纯度 80%,90%,95%,98%,99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列(单字母缩写) Ac-Val-Ala-Asp-CHO
序列(三字母缩写) Ac-Val-Ala-Asp-CHO
基本描述
溶解度
分子量 0
化学式 C14H23N3O6
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents Ac-VAD-CHO          编码
Figures Ac-VAD-CHO          编码
Reference
C端
N端
化学桥

多肽定制Ac-VAD-CHO 编码

上海金畔生物科技有限公司可以定制不同序列多肽,可以访问官网了解更多产品信息。

名称 Ac-VAD-CHO
编码
别名 Ac-VAD-CHO
纯度 80%,90%,95%,98%,99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列(单字母缩写) Ac-VAD-CHO
序列(三字母缩写) Ac-Val-Ala-Asp-CHO
基本描述
溶解度
分子量 329.4
化学式 C14H23N3O6
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents Ac-VAD-CHO          编码
Figures Ac-VAD-CHO          编码
Reference
C端
N端
化学桥

多肽定制Ac-VAD-CMK 编码

上海金畔生物科技有限公司可以定制不同序列多肽,可以访问官网了解更多产品信息。

名称 Ac-VAD-CMK
编码
别名 Ac-VAD-CMK
纯度 80%,90%,95%,98%,99%
重量 1mg,5mg,10mg,50mg,100mg,1g
序列(单字母缩写) Ac-VAD-CMK
序列(三字母缩写) Ac-Val-Ala-Asp-CMK
基本描述
溶解度
分子量 377.8
化学式 C15H24N3O6Cl1
存储条件 Store at -20°C. Keep tightly closed. Store in a cool dry place.
注释
Documents Ac-VAD-CMK          编码
Figures Ac-VAD-CMK          编码
Reference
C端
N端
化学桥